Skip to main content

Table 3 Results of a multivariate survival analysis using a Cox proportional hazards regression mode on the influence of clinicopathological variables including PgR and Ki67

From: Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index

 

RFS

CSS

Characteristics

HR

95% CI

P

HR

95% CI

P

PgR expression

  ≥ 20%

Referent

  < 20%

2.33

1.19–4.54

0.013

5.15

2.06–12.85

0.00045

Ki67 labeling index

  ≤ 10%

Referent

  > 10 and <30%

0.52

0.18–1.53

0.24

0.28

0.05–1.44

0.13

  ≥ 30%

0.69

0.33–1.47

0.34

0.68

0.29–1.57

0.36

Menopausal status

 Pre-

Referent

 Post-

1.24

0.63–2.43

0.53

0.72

0.33–1.61

0.43

Pathological T stage

 T 1–2

Referent

 T 3–4

1.49

0.68–3.25

0.32

1.51

0.58–3.90

0.40

Pathological N stage

 N 0

Referent

 N 1–3

3.16

1.51–6.58

0.0022

2.69

1.04–6.99

0.042

Histological grade

 1,2

Referent

 3

1.31

0.67–2.56

0.43

1.40

0.60–3.25

0.44

Adjuvant chemotherapy

 No

Referent

 Yes

1.37

0.71–2.64

0.35

1.25

0.55–2.82

0.59

Adjuvant endocrine therapy

 No

Referent

 Yes

1.15

0.39–3.37

0.80

1.20

0.27–5.42

0.81

  1. Abbreviations: RFS recurrence-free survival, CSS cancer-specific survival, HR hazard ratio, 95% Cl 95% Confidence interval, PgR progesterone receptor
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us